The global hematopoietic stem cell transplantation market garnered a market value of USD 7 Billion in 2023 and is expected to accumulate a market value of USD 15 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033. Because of the rising frequency of leukemia and lymphoma, the worldwide hematopoietic stem cell transplantation industry is predicted to rise significantly over the forecast period.
According to the Centers for Disease Control and Prevention (CDC), about 45,360 persons were diagnosed with leukemia in the United States in 2013, resulting in 23,549 deaths (13,625 men and 9,924 women). In accordance with the same source, men are more likely than women to have the illness. Leukemia contributes to approximately 3% of novel cancer cases.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 7 Billion |
| Anticipated Forecast Value (2033) | USD 15 Billion |
| Projected Growth Rate (2023 to 2033) | 8% CAGR |
Hematopoietic stem cell transplantation is a process in which multipotent hematopoietic stem cells are transferred into the patient from peripheral blood cells, bone marrow, or umbilical cord blood.
Lymphoma (Hodgkin and non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis are all widely treated by hematopoietic stem cell transplantation. It has two transplantation sources: autologous (using stem cells from the patient's own body) and allogeneic (using stem cells from a donor's body).
According to the World Health Organization (WHO), approximately 50,000 hematopoietic stem cell transplantation surgeries are carried out globally each year, with this figure anticipated to rise in the coming years. During the projected period, factors such as the increasing frequency of hematopoietic stem cell transplants are likely to drive market expansion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for hematopoietic stem cell transplantation is projected to increase at a CAGR of 8% during the forecast period between 2023 to 2032, reaching a total of USD 15 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6%.
The worldwide hematopoietic stem cell transplantation market is going to expand rapidly due to an increase in the frequency of hematological illnesses, an increase in transplant success rates, and growth in the world's aging population. According to a Scientific America study report, global transplantation rates have grown from 50,000 HSC transplants per year in 2012 to 75,000 HSC transplants per year in 2015. However, high transplantation costs and a shortage of financing for organizations such as the Worldwide Network for Blood and Marrow Transplantation (WBMT) are projected to limit the worldwide hematopoietic stem cell transplantation industry over the projection period.
The rising Frequency of Leukaemia and Lymphoma is Propelling the Worldwide Hematopoietic Stem Cell Transplantation Market Forward
During the projected period, the rising frequency of leukemia and lymphoma is likely to boost the hematopoietic stem cell transplantation market.
According to the Leukemia and Lymphoma Society's 2019 report, an estimated 176,200 people in the United States were diagnosed with leukemia, lymphoma, or myeloma, and roughly 1,399,180 people were living with leukemia, lymphoma, or myeloma. The rising incidence rate is predicted to fuel demand for hematopoietic stem cell transplantation, driving the hematopoietic stem cell transplantation (HSCT) industry forward.
As claimed by, the World Cancer Research Fund 2018 study, one-third of cancer cases (globally) are caused by a lack of physical exercise, obesity, and/or poor nutrition in economically developed nations such as the United States and Europe. Furthermore, 90% of leukemia starts in middle age and worsens with age.
Principal Consultant
Adverse Impacts of Hematopoietic Stem Cell Transplantation to Stifle Market Growth
The adverse impacts of hematopoietic stem cell transplantation on organs and body parts such as the gastrointestinal tract, mouth, heart, and lungs associated with the conditioning regimen and others, as well as the serious complication of graft vs. host disease, are expected to slow the market's growth.
Graft-versus-host disease (GVHD) is a consequence of both normal allogeneic and reduced-intensity allogeneic stem cell transplants in which the graft perceives the patient's healthy cells (the host) as foreign and attacks and damages them. A tight HLA match between the donor and the patient reduces but does not eliminate, the risk of GVHD. Graft-versus-host disease has three severity levels: mild, moderate, and severe. In certain situations, it can be fatal.
Increased Frequency of Blood Cancer Diseases for Widening Profit Margins
Asia-Pacific is predicted to expand during the projected timeline of 2023 to 2033 due to the increased frequency of blood cancer diseases and an increase in the number of generic manufacturers in this region.
The expansion of healthcare infrastructure and an aging population will drive the market's growth rate in this area. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7.5% in the assessment period 2023 to 2033.
Rising leukemia incidences to Drive Market Growth in the Region
Over the projected period, North America is likely to lead the entire hematopoietic stem cell transplantation market. Rising leukemia incidences and increased investment in research and development by the public and commercial sectors are the major determinants for the industry in the North American region. For example, according to data provided by the Canadian Cancer Society in May 2022, 6,700 Canadians will be diagnosed with leukemia in 2022. It was also estimated that 4,000 males will be diagnosed with leukemia, and around 2,700 women will be afflicted with leukemia, with 1,300 dying as a result. Stem cell transplants aid in the treatment of leukemia by enabling the body to replenish damaged blood cells with healthy ones.
Hematopoietic stem cells aid in the treatment of leukemia by allowing the body to replace damaged blood cells with healthy blood cells. Stem cells can differentiate into a variety of different types of cells. As a result, rising leukemia incidences are likely to drive demand for hematopoietic stem cell transplantation, fuelling market growth throughout the forecast period.
Prominent factors contributing to the expansion of the hematopoietic stem cell transplantation industry in the future include key product releases, high concentration of market participants or manufacturer's presence, acquisition & alliances among significant players, and expanding the United States. For example, according to the Leukemia and Lymphoma Society's facts and Statistics, around 90,390 persons in the United States were predicted to be diagnosed with lymphoma in 2021. (8,830 Hodgkin Lymphoma cases and 81,560 cases of Non-Hodgkin Lymphoma). As a result, North America is expected to grow at a CAGR of 7.9% in the assessment period 2023 to 2033.
Overall Increase in Transplant Success Rates fuelling the Market Growth
During the projection period, Europe is expected to lead the worldwide market. The region's supremacy is linked to an overall increase in transplant success rates, simple technical applications, and high population affluence. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 7.6% in the forecast period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Autologous Segment to enhance Sales Prospects
The worldwide hematopoietic stem cell transplantation industry is categorized into two categories: allogeneic and autologous. Despite accounting for a significant portion of the HSCT business in 2021, autologous is an important and sophisticated medical procedure employed in the treatment of a variety of malignant and non-malignant illnesses.
The Bone Marrow Transplant Segment is Predicted to Gain Traction
A bone marrow transplant is a surgery that involves injecting healthy blood-forming stem cells into the body to replace bone marrow that is not producing enough healthy blood cells. A stem cell transplant is another name for a bone marrow transplant. In individuals with malfunctioning or depleted bone marrow, a bone marrow transplant involves the introduction of healthy hematopoietic stem cells. This method is used to treat tumors that damage the bone marrow, such as leukemia, myeloma, lymphoma, and other blood and immune system illnesses.
Increased Research and Development efforts are likely to drive segment growth during the forecast period. For example, Gamida Cell Ltd. stated in October 2020 that the Phase 3 study of omidubicel, an innovative advanced cell therapy under development, is a potentially life-saving therapeutic option for patients in need of bone marrow transplant and fulfilled all three of its secondary goals.
Increased positive initiatives by the public and private sectors toward bone marrow transplants are expected to drive category expansion. For example, the QUINT founders gave around USD 16.0 million in September 2022 to create the QUINT bone marrow transplant center in Dubai. The great effectiveness and benefits of bone marrow transplant in treating acute myeloid leukemia are driving sector expansion.
Key start-up players in the hematopoietic stem cell transplantation are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key hematopoietic stem cell transplantation start-ups are as follows:
Key players in the hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio and Talaris Therapeutics.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 7 Billion |
| Market Value in 2033 | USD 15 Billion |
| Growth Rate | CAGR of 8% from 2023 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US Billion and CAGR from 2023 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Transplant Type, Indication, Application, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Pluristem Therapeutics Inc.; CellGenix GmbH; Regen Biopharma Inc.; Lonza Group; Sanofi; Taiga Biotechnologies, Inc.; Takeda Pharmaceutical Company Limited; Escape Therapeutics, Inc.; Bluebird Bio; Talaris Therapeutics |
| Customization | Available Upon Request |
Changing rules have an impact on the market by assuring the safety and quality.
Technological advancements are improving the accuracy and efficiency of transplantation.
Personalized therapy and breakthroughs in transplantation techniques.
The potential for treating numerous hematological illnesses is seeing increased usage.
The market capitalization is projected to be around USD 7 billion.
1. Executive Summary | Hematopoietic Stem Cell Transplantation Market 2. Market Overview 3. Market Background 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Transplant Type 5.1. Allogeneic 5.2. Autologous 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 6.1. Acute Myeloid Leukemia 6.2. Acute Lymphoblastic Leukemia 6.3. Hodgkin Lymphoma 6.4. Non-Hodgkin Lymphoma 6.5. Multiple Myeloma 6.6. Other Non-Malignant Disorders 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Bone Marrow Transplant 7.2. Peripheral Blood Stem Cells Transplant 7.3. Cord Blood Transplant 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East & Africa (MEA) 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Pluristem Therapeutics Inc. 16.2. CellGenix GmbH 16.3. Regen Biopharma Inc. 16.4. Lonza Group 16.5. Sanofi 16.6. Taiga Biotechnologies, Inc. 16.7. Takeda Pharmaceutical Company Limited 16.8. Escape Therapeutics, Inc. 16.9. Bluebird Bio 16.10. Talaris Therapeutics 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Hematopoietic Stem Cell Transplantation Market
